β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI] </= 25 kg/m(2)), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of beta-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, beta-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.1-7.7 mmol/liter), beta-cell glucose sensitivity declined by 50-70% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective beta-cell potentiation and rate sensitivity also emerged (P </= 0.05). In the whole data set, insulin sensitivity and the dynamic parameters of beta-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) beta-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of beta-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The slope of the relationship between glucose and insulin secretion (ie, β -CGS) is a major controller of postprandial glu cose levels (23, 24).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [24]
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“5] -cell glucose sensitivity (pmol min 1 m 2 mM (1)) 147 [97] 92 [98] 55 [34] 14 [15]”
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Fasting plasma insulin (pmol/liter) 20 [16] 48 [32] 74 [47] 94 [58] Insulin AUC (nmol/liter h) 22 [15] 45 [38] 65 [33] 24 [23] I/ G (pmol/mmol) 73 [84] 163 [172] 122 [140] 19 [33] Fasting ISR (pmol/min m (2)) 53 [34] 85 [53] 116 [39] 112 [71] Total IS (nmol m (2)) 30 [18] 43 [19] 47 [17] 24 [19] Insulin sensitivity (M…”
Cited by
Items 101–200 of 538
Abdul-Ghani, M. A., Matsuda, M., Jani, R., Jenkinson, C. P., Coletta, D. K., Kaku, K., & DeFronzo, R. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00674.2007 · Cited by 91
Self-citationActos Now for the prevention of diabetes (ACT NOW) study
DeFronzo, R. A., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R., et al. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-17 · Cited by 89
“Individuals with IGT are characterized by defects in both insulin secretion and insulin sensitivity [20-22].”
Self-citationBugliani, M., Liechti, R., Cheon, H., Suleiman, M., Marselli, L., Kirkpatrick, C. L., Filipponi, F., Boggi, U., Xénarios, I., Syed, F., et al. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.12.001 · Cited by 99
Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose tolerance
Muscelli, E., Mari, A., Natali, A., Astiarraga, B. D., Camastra, S., Frascerra, S., Holst, J. J., & Ferrannini, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00571.2005 · Cited by 87
“IGT subjects frequently are insulin resistant (19) and display similar defects in -cell function as overtly diabetic patients, only of a lesser degree (9, 10, 34).”
BackgroundSelf-citationTreatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 113
Assessment of insulin secretion in relation to insulin resistance
Mari, A., Ahrén, B., & Pacini, G. (2005) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000171130.23441.59 · Cited by 87
Self-citationSebbagh, N., Cruciani‐Guglielmacci, C., Ouali, F., Berthault, M., Rouch, C., Sari, D. C., & Magnan, C. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.10.005 · Cited by 103
“[7] Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo R.”
BackgroundRijkelijkhuizen, J. M., Girman, C. J., Mari, A., Alssema, M., Rhodes, T., Nijpels, G., Kostense, P. J., Stein, P. P., Eekhoff, E. M. W., Heine, R. J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.11.017 · Cited by 91
Self-citationDisordered insulin secretion in the development of insulin resistance and Type 2 diabetes
Schofield, C. J., & Sutherland, C. D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03655.x · Cited by 90
Ottosson-Laakso, E., Krus, U., Storm, P., Prasad, R. B., Oskolkov, N., Ahlqvist, E., Fadista, J., Hansson, O., Groop, L., & Vikman, P. J. (2017) · Diabetes · doi:10.2337/db17-0311 · Cited by 89
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Self-citationKanat, M., DeFronzo, R. A., & Abdul-Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 82
Self-citationTime to glucose peak during an oral glucose tolerance test identifies prediabetes risk
Chung, S. T., Ha, J., Onuzuruike, A. U., Kasturi, K., Cruz, M. G. L., Bingham, B. A., Baker, R. L., Utumatwishima, J. N., Mabundo, L. S., Ricks, M., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13416 · Cited by 90
Forbes, S., Oram, R. A., Smith, A., Lam, A., Olateju, T., Imes, S., Malcolm, A. J., Shapiro, A. M. J., & Senior, P. A. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13807 · Cited by 80
“Assessment of graft function, like the assessment of beta cell mass in diabetes (11,12), is complex.”
Backgroundβ-Cell failure in type 2 diabetes
Leibowitz, G., Kaiser, N., & Cerasi, E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00094.x · Cited by 78
Castro, F. G., Shaibi, G. Q., & Boehm-Smith, E. (2009) · Journal of Behavioral Medicine · doi:10.1007/s10865-008-9194-z · Cited by 78
“…addressing existing health disparities among racial/ethnic minority populations involves the design of scientifically based prevention interventions (Flay et al. 2005) that are also culturally sensitive (Kumpfer et al. 2002) for promoting healthy behavior change within various special populations.”
BackgroundAdaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance
Gastaldelli, A., Abdul Ghani, M., & DeFronzo, R. A. (2021) · Diabetes · doi:10.2337/db19-1152 · Cited by 75
“(3); for modeling analyses, we used the MLAB software (Civilized Software, Silver Spring, MD).”
MethodInfluentialSelf-citationAhmed, D., Kumar, V., Sharma, M., & Verma, A. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-155 · Cited by 88
“On the other hand, impaired glucose-induced insulin secretion (GIIS) with a decrease in pancreatic -cell mass will eventually lead to chronic hyperglycaemia [7].”
BackgroundInsulin Clearance in Health and Disease
Najjar, S. M., Caprio, S., & Gastaldelli, A. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031622-043133 · Cited by 72
Self-citationBurns, S. F., Bacha, F., Lee, S. J., Tfayli, H., Gungor, N., & Arslanian, S. A. (2011) · Diabetes Care · doi:10.2337/dc11-0423 · Cited by 75
“Others (24) have demonstrated similar findings.”
Semwal, D. K., Kumar, A., Aswal, S., Chauhan, A., & Semwal, R. B. (2020) · Phytotherapy Research · doi:10.1002/ptr.6885 · Cited by 86
“Decreased sensitivity to glucose in which the normal sensitivity threshold has wide individual variations not affecting their ability to maintain glucose homeostasis, the sensitivity of β-cells to glucose decreases progressively from impaired glucose tolerance to T2DM (Ferrannini et al., 2005).”
BackgroundManaging insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Self-citationPunithavathi, V. R., Stanely Mainzen Prince, P., Kumar, M. R., & Selvakumari, C. J. (2011) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20360 · Cited by 74
“On the other hand, impaired glucose induced insulin secretion with a decrease in pancreatic β cell mass will eventually lead to chronic hyperglycemia [5].”
BackgroundIs insulin resistance the cause of the metabolic syndrome?
Ferrannini, E. (2006) · Annals of Medicine · doi:10.1080/07853890500415358 · Cited by 86
“Finally, and perhaps more importantly, the relationship between insulin action and ß-cell function is highly non-linear, such that even small decrements in the ability of the ß-cell to sense glucose result in impaired glucose tolerance when coupled with insulin resistance (14) (Figure 2).”
BackgroundSelf-citationShankar, S. S., Vella, A. V., Raymond, R. H., Staten, M. A., Calle, R. A., Bergman, R. N., Cao, C., Chen, D., Cobelli, C., Man, C. D., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0931 · Cited by 77
Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index
Tura, A., Chemello, G., Szendroedi, J., Göbl, C. S., Færch, K., Vrbíková, J., Pacini, G., Ferrannini, E., & Roden, M. (2018) · Diabetologia · doi:10.1007/s00125-018-4568-4 · Cited by 78
Self-citationWallander, M., Bartnik, M., Efendić, S., Hamsten, A., Malmberg, K., Öhrvik, J., Rydén, L., Silveira, A. M. V., & Norhammar, A. (2005) · Diabetologia · doi:10.1007/s00125-005-1931-z · Cited by 78
HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes
Ilegems, E., Bryzgalova, G., Correia, J. C., Yesildag, B., Berra, E., Ruas, J. L., Pereira, T., & Berggren, P. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9112 · Cited by 78
Bruin, J. E., Saber, N., Braun, N., Fox, J. K., Mojibian, M., Asadi, A., Drohan, C., O’Dwyer, S., Rosman-Balzer, D. S., Swiss, V. A., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.011 · Cited by 72
“, 2003) and declining beta cell function during the progression from pre-diabetes to overt diabetes (Weyer et al., 1999; Ferrannini et al., 2005).”
BackgroundAuthors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 87
Self-citationfor the ACT NOW Study Group, DeFronzo, R. A., Banerji, M. A., Bray, G. A., Buchanan, T. A., Clément, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S. R. D., Musi, N., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1614-2 · Cited by 80
“Using the insulin clamp, we [19, 20, 25, 26 ]a nd others [29, 30] have shown that persons with IGT are resistant to insulin.”
MethodSelf-citationZhyzhneuskaya, S. V., Al-Mrabeh, A., Peters, C., Barnes, A., Aribisala, B., Hollingsworth, K. G., McConnachie, A., Sattar, N., Lean, M. E. J., & Taylor, R. (2020) · Diabetes Care · doi:10.2337/dc19-0371 · Cited by 70
Sun, H., Temeck, J. W., Chambers, W., Perkins, G., Bonnel, R., & Murphy, D. (2018) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017725558 · Cited by 70
“Second, children have a shorter latency period and lower glycosylated hemoglobin, in part because there is less time for the development of glucose dysregulation.(22,24-27) Finally, children have a higher incidence of ketoacidosis and glucose toxicity at diagnosis.”
Jensen, D. H., Aaboe, K., Henriksen, J. E., Vølund, A., Holst, J. J., Madsbad, S., & Krarup, T. (2012) · Diabetologia · doi:10.1007/s00125-012-2459-7 · Cited by 76
“glucose is impaired early in the development of type 2 diabetes, and is one of the factors determining the progression from normal to abnormal glucose tolerance [44].”
BackgroundType 2 diabetes mellitus—current therapies and the emergence of surgical options
Lebovitz, H. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.10 · Cited by 73
“During the progressive decline in β-cell function that occurs with increasing duration of T2DM”
BackgroundMartínez-Cerón, E., Fernández-Navarro, I., & Rio, F. G. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.03.002 · Cited by 77
Zhuang, Y., Yang, X., Li, Y., Chen, Y., Peng, X., Yu, L., & Ding, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b10346 · Cited by 69
β Cell function and plasma insulin clearance in people with obesity and different glycemic status
Mittendorfer, B., Patterson, B. W., Smith, G. I., Yoshino, M., & Klein, S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154068 · Cited by 61
“ISRs during basal conditions and after glucose ingestion are usually 45% higher in individuals with obesity than in those who are lean (39).”
BackgroundPrediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., Mudaliar, S., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0520 · Cited by 65
Self-citationMicrobial Regulation of Glucose Metabolism and Insulin Resistance
Crommen, S., & Simon, M.-C. (2017) · Genes · doi:10.3390/genes9010010 · Cited by 65
Abdul-Ghani, M., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
Self-citationThe β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 80
“Thus, for example, it has been reported that (i) insulin secretion rates are increased in obese individuals (554); (ii) β-cell function decreases progressively as glucose tolerance declines in adults (554) and youth (555-557); (iii) the response to bariatric surgery is dependent on β-cell function at baseline, with a…”
BackgroundAnsari, M. A., Chauhan, W., Shoaib, S., Alyahya, S. A., Ali, M., Ashraf, H., Alomary, M. N., & Al-Suhaimi, E. A. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01369-3 · Cited by 73
“All kinds of diabetes patients are susceptible to the same physiology once hyperglycemia sets in, though progression rates may vary [61 – 63].”
BackgroundAssociation between renin and atherosclerotic burden in subjects with and without type 2 diabetes
Gonçalves, I., Edsfeldt, A., Colhoun, H. M., Shore, A. C., Palombo, C., Natali, A., Fredrikson, G. N., Björkbacka, H., Wigren, M., Bengtsson, E., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0346-8 · Cited by 64
Rangel, É. B. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.964205 · Cited by 66
“Of importance, b-cell damage and IR, also present in type 2 diabetes, are not separate entities because IR indicates 50 -- 70% loss of b-cell mass [103].”
BackgroundGoals of Treatment for Type 2 Diabetes
Marchetti, P., Lupi, R., Guerra, S. D., Bugliani, M., D’Aleo, V., Occhipinti, M., Boggi, U., Marselli, L., & Masini, M. (2009) · Diabetes Care · doi:10.2337/dc09-s306 · Cited by 70
“Moreover, dynamic parameters of -cell function were independent determinants of prevailing plasma glucose concentrations throughout the glucose tolerance interval (6).”
BackgroundBariatric Surgery in Patients With Morbid Obesity and Type 2 Diabetes
Schernthaner, G., & Morton, J. M. (2008) · Diabetes Care · doi:10.2337/dc08-s270 · Cited by 70
An examination of β‐cell function measures and their potential use for estimating β‐cell mass
Kahn, S. E., Carr, D. B., Faulenbach, M. V., & Utzschneider, K. M. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00945.x · Cited by 60
Thunander, M., Törn, C., Petersson, C., Ossiansson, B., Fornander, J., & Landin‐Olsson, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0797 · Cited by 70
Podell, B. K., Ackart, D. F., Richardson, M. A., DiLisio, J. E., Pulford, B. E., & Basaraba, R. J. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.025593 · Cited by 68
“…of increased insulin demand along with a reduction in functional β -cell mass is designed to mimic crucial manifestations in the pathogenesis of human type 2 diabetes, which can be accomplished within a condensed time frame (Kahn, 2001; Ferrannini et al., 2005; Weir and Bonner-Weir, 2013).”
Prediabetes: The Importance of Early Identification and Intervention
Hsueh, W. A., Orloski, L., & Wyne, K. L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2180 · Cited by 71
“Accordingly, marked deterioration in β-cell function precedes the onset of type 2 diabetes.(52,53) A recent study of the relationship between fasting hyperglycemia and insulin secretion in individuals with normal glucose tolerance or IGT suggested that even small increases in FPG levels within the normal range are ass…”
BackgroundRodríguez‐Rodríguez, A. E., Triñanes, J., Velázquez-García, S., Porrini, E., Prieto, M. J. V., Fuentes, M. L. D., Arévalo, M. A., SALIDO, E. C., & Torres, A. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12236 · Cited by 62
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 69
Mari, A., Tura, A., Pacini, G., Kautzky‐Willer, A., & Ferrannini, E. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02441.x · Cited by 63
Self-citationβ-Cell Failure or β-Cell Abuse?
Erion, K., & Corkey, B. E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00532 · Cited by 67
Brain control of blood glucose levels: implications for the pathogenesis of type 2 diabetes
Alonge, K. M., D’Alessio, D. A., & Schwartz, M. W. (2020) · Diabetologia · doi:10.1007/s00125-020-05293-3 · Cited by 70
β-Cell preservation with thiazolidinediones
Campbell, I. W., & Mariz, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.08.015 · Cited by 61
The Relationship Between β-Cell Function and Glycated Hemoglobin
Kanat, M., Winnier, D., Norton, L., Arar, N., Jenkinson, C., DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1352 · Cited by 58
Self-citationTfayli, H., Lee, S., & Arslanian, S. (2010) · Diabetes Care · doi:10.2337/dc09-2292 · Cited by 57
“However, the study included subjects with impaired glucose tolerance and with overt diabetes and reported a detectable decline in GDI only in the subjects with type 2 diabetes (22).”
BackgroundMethodPetrie, J. R., Pearson, E. R., & Sutherland, C. D. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.11.010 · Cited by 68
Odori, S., Hosoda, K., Tomita, T., Fujikura, J., Kusakabe, T., Kawaguchi, Y., Doi, R., Takaori, K., Ebihara, K., Sakai, Y., et al. (2012) · Metabolism · doi:10.1016/j.metabol.2012.06.010 · Cited by 60
Abdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55
Self-citationTura, A., Muscelli, E., Gastaldelli, A., Ferrannini, E., & Mari, A. (2014) · Diabetologia · doi:10.1007/s00125-014-3219-7 · Cited by 59
Self-citationNing, F., Zhang, L., Dekker, J. M., Onat, A., Stehouwer, C. D., Yudkin, J. S., Laatikainen, T., Tuomilehto, J., Pyörälä, K., Qiao, Q., et al. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-76 · Cited by 55
“; licensee BioMed Central Lt Commons Attribution License (http://creativec reproduction in any medium, provided the or cell function are already presented in subjects with elevated normal FPG and/or 2hPG [11-13].”
BackgroundWang, X., Zhao, X., Zhou, R., Gu, Y., Zhu, X., Tang, Z., Yuan, X., Chen, W., Zhang, R., Chen, Q., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12834 · Cited by 61
Prince, P. S. M., Kumar, M. R., & Selvakumari, C. J. (2010) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20365 · Cited by 58
“Impaired glucoseinduced insulin secretion with a decrease in pancreatic β cell mass will eventually lead to chronic hyperglycemia [2].”
BackgroundElder, D. A., Wooldridge, J. L., Dolan, L. M., & D’Alessio, D. A. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.05.012 · Cited by 55
(How) Can We Prevent Type 2 Diabetes?
Buchanan, T. A. (2007) · Diabetes · doi:10.2337/db07-0140 · Cited by 55
Schindler, T. H., Facta, A. D., Prior, J. O., Cadenas, J., Hsueh, W. A., Quiñones, M. J., & Schelbert, H. R. (2006) · Heart · doi:10.1136/hrt.2006.094128 · Cited by 56
“Furthermore, the lower plasma insulin concentrations in the patients may also reflect a later stage of diabetic disease at which insulin secretion had already sufficiently declined.”
BackgroundIncreased skeletal muscle capillarization enhances insulin sensitivity
Akerstrom, T., Laub, L., Vedel, K., Brand, C. L., Pedersen, B. K., Lindqvist, A. K., Wojtaszewski, J. F. P., & Hellsten, Y. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00020.2014 · Cited by 54
“These data point toward the importance of increasing skeletal muscle capillarization for prevention or treatment of type 2 diabetes. capillarization; skeletal muscle; insulin sensitivity; muscle glucose uptake INSULIN RESISTANCE IN SKELETAL MUSCLE is one of the key impairments that underlie the pathogenesis of impaire…”
BackgroundInfluentialWalker, M., Mari, A., Jayapaul, M. K., Bennett, S. M. A., & Ferrannini, E. (2005) · Diabetologia · doi:10.1007/s00125-005-0004-7 · Cited by 55
“It has been observed that this potentiation ratio is greater than 1 in normal subjects (representing a relative increase in insulin secretion in relation to the glucose levels over the course of the OGTT), and is progressively depressed as glucose tolerance worsens [20].”
BackgroundSelf-citationVisceral fat and beta cell function in non-diabetic humans
Gastaldelli, A., Sironi, A. M., Ciociaro, D., Positano, V., Buzzigoli, E., Giannessi, D., Lombardi, M., Mari, A., & Ferrannini, E. (2005) · Diabetologia · doi:10.1007/s00125-005-1891-3 · Cited by 61
“As previously shown, the dynamic properties of the beta cell are key determinants of oral glucose tolerance [5, 6], while insulin resistance, primary or secondary to obesity, feeds back to the beta cell by enhancing its tone or set point.”
BackgroundMethodSelf-citationEarly therapy for type 2 diabetes in China
Yang, W., & Weng, J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70136-6 · Cited by 57
Salgin, B., Marcovecchio, M. L., Humphreys, S. M., Hill, N., Chassin, L. J., Lunn, D. J., Hovorka, R., & Dunger, D. B. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90613.2008 · Cited by 52
“It is not known when -cell dysfunction first appears in the development of T2D, but recent evidence (15) suggests it occurs when glucose tolerance is still classified as normal.”
BackgroundInfluence of Hyperinsulinemia and Insulin Resistance on In Vivo β-Cell Function
Mari, A., Tura, A., Natali, A., Anderwald, C., Balkau, B., Lalic, N., Walker, M., Ferrannini, E., & for the RISC Investigators (2011) · Diabetes · doi:10.2337/db11-0827 · Cited by 52
“The acute insulin secretory response to the intravenous glucose bolus (glucose-induced secretory response [GISR]) was expressed as the mean incremental C-peptide concentration during the first 8 min after the glucose bolus (GISRC-pep) as well as the ratio of incremental insulin secretion (calculated by C-peptide decon…”
BackgroundInfluentialSelf-citationChase, J. G., Desaive, T., Bohé, J., Cnop, M., Block, C. E. M. D., Gunst, J., Hovorka, R., Kalfon, P., Krinsley, J. S., Renard, É., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2110-1 · Cited by 58
Health risks and interventions in prediabetes: A review
Mahat, R. K., Singh, N., Arora, M., & Rathore, V. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.041 · Cited by 52
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Self-citationde Paula, A. L., Stival, A. R., Halpern, A., DePaula, C. C. L., Mari, A., Muscelli, E., Vencio, S. A. C., & Ferrannini, E. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1550-6 · Cited by 60
“Glucose sensitivity (pmolminmmM) Pre 16 [21] 19 [20] 15 [47] ns”
Self-citationMovassat, J., Bailbé, D., Lubrano-Berthelier, C., Picarel-Blanchot, F., Bertin, É., Mourot, J., & Portha, B. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00501.2007 · Cited by 53
“Importantly, studies in humans also report that -cell dysfunction could be a proximal defect in the process of developing glucose intolerance and diabetes (12, 14, 23, 47).”
Backgroundβ-Cell Function in Severely Obese Type 2 Diabetic Patients
Camastra, S., Manco, M., Mari, A., Greco, A. V., Frascerra, S., Mingrone, G., & Ferrannini, E. (2007) · Diabetes Care · doi:10.2337/dc06-1845 · Cited by 51
“Overt diabetes and impaired glucose tolerance, on the other hand, are characterized by a progressive loss of -cell glucose sensitivity independent of insulin resistance (6).”
BackgroundSelf-citationDiabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis
Wilkin, T. J. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00343.x · Cited by 49
Bergman, M., Jagannathan, R., Buysschaert, M., Pareek, M., Olsen, M. H., Nilsson, P. M., Medina, J. L., Roth, J., Chetrit, A., Groop, L., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2992 · Cited by 56
“Finally, Ferrannini et al also demonstrated that within the NGT range, β‐cell glucose sensitivity declined by 50% to 70% in association with rising 2‐hour PG concentrations although absolute insulin secretion rates increased.(34)”
BackgroundGlucokinase, the pancreatic glucose sensor, is not the gut glucose sensor
Murphy, R., Tura, A., CLARK, P. M. S., Holst, J. J., Mari, A., & Hattersley, A. T. (2008) · Diabetologia · doi:10.1007/s00125-008-1183-9 · Cited by 53
“This is in agreement with previous studies [28] that have shown that hyperglycaemic states are accompanied by a decrease in the potentiation factor, which is progressively reduced as glucose tolerance worsens.”
ResultSelf-citationMcCurley, J. L., Mills, P. J., Roesch, S. C., Carnethon, M. R., Giacinto, R. E., Isasi, C. R., Teng, Y., Sotres‐Alvarez, D., Llabre, M. M., Penedo, F. J., et al. (2015) · Psychophysiology · doi:10.1111/psyp.12430 · Cited by 56
“…β-cell impairment (i.e., impairment of the pancreatic cells that produce insulin) can be observed many years before the onset of clinical diabetes (Ferrannini et al., 2005; Tabak, Herder, Rathmann, Brunner, & Kivimaki, 2012) This has led to an interest in identifying and intervening at earlier…”
BackgroundLipid-induced β-cell dysfunction in vivo in models of progressive β-cell failure
Goh, T. T., Mason, T. M., Gupta, N., So, A., Lam, T. K. T., Lam, L., Lewis, G. F., Mari, A., & Giacca, A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00255.2006 · Cited by 48
Self-citationDocherty, P. D., Chase, J. G., Lotz, T., Hann, C. E., Shaw, G. M., Berkeley, J. E., Mann, J. I., & McAuley, K. (2009) · The Open Medical Informatics Journal · doi:10.2174/1874431100903010065 · Cited by 52
“5 Poor repeatability in terms of re-classification rate [7, 14, 16]”
BackgroundScheen, A. J. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2006.11.005 · Cited by 52
Dynamic assessment of insulin secretion and insulin resistance in Asians with prediabetes
Magkos, F., Lee, M. H., Lim, M., Cook, A. R., Chhay, V., Loh, T. P., Chia, K. S., Baig, S., Ang, I. Y. H., Tay, J., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154957 · Cited by 53
Maganti, A. V., Maier, B., Tersey, S. A., Sampley, M. L., Mosley, A. L., Özcan, S., Pachaiyappan, B., Woster, P. M., Hunter, C. S., Stein, R. W., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616219 · Cited by 47
“Deficiency of insulin secretion underlies the transition from normoglycemia to hyperglycemia in both type 1 and type 2 diabetes (1, 2).”
BackgroundMohan, R., Baumann, D. C., & Alejandro, E. U. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00072.2018 · Cited by 54
Petrofsky, J. S. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500319 · Cited by 44
Lavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14650 · Cited by 44
“OGTT-derived indices of insulin sensitivity and insulin secretion were calculated from plasma glucose, insulin, and C-peptide concentrations during OGTT, as previously described.(20,21) The Matsuda Index and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) were used to quantitate insulin sensitivity.”
MethodSelf-citationChávez, A. O., Coletta, D. K., Kamath, S., Cromack, D. T., Monroy, A., Folli, F. B., DeFronzo, R. A., & Tripathy, D. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90737.2008 · Cited by 46
“Insulin secretion indexes were calculated as the ratio of the incremental insulin-to-glucose response during the first 30 min ( I0–30/ G0–30) and during the 0–120 min ( I0–120/ G0–120) of the OGTT (13).”
MethodSelf-citationThewjitcharoen, Y., Elizabeth, A. J., Butadej, S., Nakasatien, S., Chotwanvirat, P., Wanothayaroj, E., Krittiyawong, S., Himathongkam, T., & Himathongkam, T. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0339-6 · Cited by 232
“In vivo studies in humans indicated that there is a 70% decrease in beta-cell glucose responsiveness by the time that individual has developed IGT [19].”
Eldor, R., & Raz, I. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.004 · Cited by 54
“Both of these deleterious processes have been strongly linked to visceral fat accumulation and obesity [1,2].”
BackgroundPrenatal Programming of Insulin Secretion in Intrauterine Growth Restriction
Gatford, K. L., & Simmons, R. A. (2013) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31829e5b29 · Cited by 47
Sathananthan, A., Man, C. D., Zinsmeister, A. R., Camilleri, M., Rodeheffer, R. J., Toffolo, G., Cobelli, C., Rizza, R. A., & Vella, A. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04159.x · Cited by 43
Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study
Ferrannini, E., Massari, M., Nannipieri, M., Natali, A., López‐Ridaura, R., & Gonzales-Villalpando, C. (2009) · Diabetologia · doi:10.1007/s00125-009-1289-8 · Cited by 44
“In contrast, 2 h plasma glucose levels are principally the result of glucose-induced insulin secretion (in particular, beta cell glucose sensing) and insulin-stimulated glucose clearance [ 17 ].”
BackgroundSelf-citationAngellotti, E., D’Alessio, D., Dawson-Hughes, B., Nelson, J., Cohen, R. M., Gastaldelli, A., & Pittas, A. G. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00015 · Cited by 42
“The primary endpoint was change from baseline to 24 weeks in insulin secretion rate (ISR), estimated from glucose and C-peptide from the OGTT by deconvolution analysis using a twocompartmentmodel with standard parameters for C-peptide kinetics [17, 18].”
MethodSelf-citation
Metadata
- Authors
- Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A.
- Affiliations
- University of Pisa (IT)
- The University of Texas at San Antonio Health Science Center (US)
- National Research Council (IT)
- Corresponding author
- Ferrannini, Ele
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 493-500
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1981581852
- Semantic Scholar
- 1e59c003bc095926431f049735ca1064ebb24a32
- Cited by
- 540
- References
- 45
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 27 · 2021: 19 · 2020: 21 · 2019: 22 · 2018: 25 · 2017: 26 · 2016: 21 · 2015: 33 · 2014: 33 · 2013: 26 · 2012: 32
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 24092)
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- beta-cell function, type 2 diabetes, impaired glucose tolerance, insulin sensitivity, insulin secretion rate, beta-cell glucose sensitivity, rate dependence, C-peptide, hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, obesity, 2-hour plasma glucose
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Fatty Acids, Nonesterified, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Islets of Langerhans, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.